Envestnet Asset Management
TBPH icon

Envestnet Asset Management’s Theravance Biopharma TBPH Stock Holding History

Envestnet Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-677
Closed -$15K – 2459
2018
Q2 		$15K Buy
677
+76
+13% +$1.8K ﹤0.01% 2479
2018
Q1 		$15K Buy
601
+278
+86% +$7.63K ﹤0.01% 2433
2017
Q4 		$9K Buy
323
+26
+9% +$769 ﹤0.01% 2657
2017
Q3 		$10K Buy
297
+104
+54% +$3.4K ﹤0.01% 2603
2017
Q2 		$8K Buy
+193
New +$7.42K ﹤0.01% 2755

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Envestnet Asset Management's TBPH Position: Q3 2018 in Review

Envestnet Asset Management sold out of Theravance Biopharma (TBPH) in Q3 2018, closing a stake of 677 shares — an estimated $15K sold.

Envestnet Asset Management first reported a position in TBPH in Q2 2017 and held it in 5 quarters. The position peaked at $15K in Q2 2018. 93 funds tracked by Wall St. Rank hold TBPH as of Q3 2018.

  • Envestnet Asset Management reported no remaining Theravance Biopharma position as of Q3 2018 after selling out during the quarter.
  • Envestnet Asset Management sold 677 Theravance Biopharma shares in Q3 2018, an estimated $15K.
  • Envestnet Asset Management first reported a position in Theravance Biopharma in Q2 2017 and held it in 5 quarters.
  • Envestnet Asset Management's Theravance Biopharma position peaked at $15K in Q2 2018.
  • 93 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2018.

Based on Envestnet Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.